docetaxel anhydrous has been researched along with montelukast in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (montelukast) | Trials (montelukast) | Recent Studies (post-2010) (montelukast) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,965 | 598 | 777 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | montelukast (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.197 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.702 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.488 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.689 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.919 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.434 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.7 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 8.045 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 5.279 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 6.626 | |
| Substance-K receptor | Homo sapiens (human) | 3.822 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.689 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.525 | |
| D(3) dopamine receptor | Homo sapiens (human) | 7.747 | |
| Delta-type opioid receptor | Homo sapiens (human) | 4.795 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 6.256 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.601 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.856 | |
| Leukotriene C4 synthase | Homo sapiens (human) | 5 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beloglazkina, EK; Ber, AP; Borisova, YA; Chepikova, OE; Erofeev, A; Gorelkin, P; Khazanova, ES; Khudyakov, AD; Kolmogorov, VS; Kovalev, S; Machulkin, AE; Majouga, AG; Nimenko, EA; Pankratov, AA; Petrov, SA; Plotnikova, EA; Pokrovsky, VS; Polshakov, VI; Shafikov, RR; Skvortsov, DA; Smirnova, GB; Uspenskaya, AA; Vaneev, AN; Zamyatnin, AA; Zyk, NU; Zyk, NV | 1 |
1 review(s) available for docetaxel anhydrous and montelukast
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for docetaxel anhydrous and montelukast
| Article | Year |
|---|---|
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
Topics: Antigens, Surface; Cell Line, Tumor; Coordination Complexes; Glutamate Carboxypeptidase II; Humans; Male; Microsomes, Liver; Oligopeptides; Prostatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |